<DOC>
	<DOCNO>NCT02710500</DOCNO>
	<brief_summary>The propose clinical trial double-blind , randomize control study direct intramuscular injection rAAVrh.74.MHCK7.DYSF.DV gene vector extensor digitorum brevis muscle ( EDB ) . Two cohort subject dysferlin deficiency , proven mutation undergo gene transfer . A minimum three subject enrol cohort .</brief_summary>
	<brief_title>rAAVrh74.MHCK7.DYSF.DV Treatment Dysferlinopathies</brief_title>
	<detailed_description>This phase I safety tolerability study direct intramuscular injection rAAVrh.74.MHCK7.DYSF.DV transfer extensor digitorum brevis muscle ( EDB ) . The study design randomize , control , dose escalation trial one EDB receive rAAVrh.74.MHCK7.DYSF.DV side receive saline alone . It follow previously safe effective IM gene transfer EDB LGMD2D.2 , 3 The first cohort , inclusive three Dysferlinopathy subject , receive gene transfer total dose 2 x 10^12 vector genome . Muscle biopsy perform Day 45 ( two subject ) Day 90 ( one subject ) . If safety concern , three additional subject enrol receive escalate dose 6 X 10^12 vg ( total dose ) . Muscle biopsy second cohort perform Day 90 ( one subject ) Day 180 ( two subject ) . This protocol design give u maximum period observation range 6 week 6 month capture transient delay gene expression , recognize sustained expression .</detailed_description>
	<mesh_term>Muscular Dystrophies , Limb-Girdle</mesh_term>
	<criteria>Must Nonambulant ( walk 10 meter ≤ 30 sec ) age 18 year old Established mutation dysferlin gene allele Impaired muscle function sufficient muscle preservation ensure muscle transfection base magnetic resonance image EDB show sufficient muscle preservation permit transfection Willingness sexually active subject reproductive capacity practice reliable method contraception ( If appropriate ) , first six month gene transfer ( female ) two negative sperm sample obtain post gene transfer ( male ) . Active viral infection base clinical observation serological evidence HIV , Hepatitis A , B C infection The presence Dysferlin mutation without weakness loss function Symptoms sign cardiomyopathy , include : Dyspnea exertion , pedal edema , shortness breath upon lie flat , rales base lung Echocardiogram ejection fraction 40 % Diagnosis ( ongoing treatment ) autoimmune disease Persistent leukopenia leukocytosis ( WBC ≤ 3.5 K/µL ≥ 20.0 K/µL ) absolute neutrophil count &lt; 1.5K/µL Concomitant illness requirement chronic drug treatment opinion PI create unnecessary risk gene transfer Pregnancy AAVrh74 AAV8 bind antibody titer &gt; 1:50 determined ELISA immunoassay Abnormal laboratory value clinically significant range table , base upon normal value Nationwide Children 's Hospital Laboratory : GGT , Total Bilirubin , Cystatine , Hemoglobin , White Blood Cells</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>LGMD2B</keyword>
	<keyword>Limb Girdle Muscular Dystrophy</keyword>
	<keyword>Miyoshi</keyword>
	<keyword>Gene Transfer</keyword>
	<keyword>Dysferlin</keyword>
</DOC>